本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 四川和邦生物科技股份有限公司（以下简称"公司"）于 2023 年 9 月 5 日召 开第六届董事会第四次会议，审议通过了《关于聘任公司董事会秘书的议案》， 同意聘任蒋思颖女士为公司董事会秘书，任期自本次董事会审议通过之日起至公 司第六届董事会任期届满为止。（蒋思颖女士简历附后） 蒋思颖女士已取得董事会秘书资格证书，其任职资格符合《中华人民共和国 公司法》（以下简称《公司法》）《上海证券交易所股票上市规则》等相关法律法 规的要求。 证券代码：603077 证券简称：和邦生物 公告编号：2023-51 四川和邦生物科技股份有限公司 关于聘任董事会秘书的公告 公司董事会秘书联系方式如下： 特此公告。 四川和邦生物科技股份有限公司董事会 2023 年 9 月 6 日 电话：028-62050230 传真：028-62050290 邮箱：jsy@hebang.cn 地址：四川省成都市青羊区广富路 8 号 C6 幢 附：董事会秘书蒋思颖女士简历 蒋思颖：女，汉族，1988 年出生，中国籍，无 ...

证券代码：603077 证券简称：和邦生物 公告编号：2023-50 四川和邦生物科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、担保情况概述 （一）担保基本情况 2023 年 8 月 9 日，公司与汇丰银行（中国）有限公司签订《保证书》，为 公司控股子公司四川武骏光能股份有限公司（以下简称"武骏光能"）之全资子 公司重庆武骏提供担保，保证方式为连带责任保证，合同所保证最高债务金额为 人民币 0.50 亿元，保证期间为自债权确定期间的终止之日起三年，重庆武骏其 他少数股东未提供同比例担保，本次担保不存在反担保。 （二）公司本次担保事项履行的内部决策程序 公司于 2023 年 2 月 20 日召开第五届董事会第二十次会议、2023 年 5 月 12 日召开 2022 年年度股东大会会议，审议通过《关于 2023 年公司对外担保授权的 议案》，公司对全资及控股子公司提供担保、子公司之间互相提供担保（包括银 被担保人名称：武骏重庆光能有限公司（以下简称"重庆武骏"），为 四川和邦生物科技股份有限 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with total revenue reaching RMB 500 million, representing a 25% year-over-year growth[12]. - The company's operating revenue for the first half of 2023 was approximately CNY 7.48 billion, a decrease of 45.31% compared to the same period last year[17]. - The net profit attributable to shareholders was approximately CNY 2.63 billion, down 76.60% year-on-year[17]. - Basic earnings per share decreased to CNY 0.0707, a decline of 76.59% compared to CNY 0.3020 in the previous year[18]. - The weighted average return on equity dropped to 3.17%, a decrease of 13.61 percentage points from the previous year[18]. - The company reported a net cash flow from operating activities of approximately CNY 1.74 billion, down 80.48% year-on-year[17]. - The company achieved operating revenue of 4.09 billion RMB in the first half of 2023, a decrease of 45.31% compared to the same period last year[38]. - The net profit attributable to shareholders was 617 million RMB, reflecting the impact of macroeconomic conditions and market supply-demand changes[37]. Market and Product Development - User data indicates a growing customer base, with active users increasing by 15% compared to the previous year, now totaling 1.2 million[12]. - The company has provided a positive outlook for the second half of 2023, projecting a revenue growth of 20% to 30% based on current market trends and demand[12]. - New product development includes the launch of a novel biopesticide, expected to contribute an additional RMB 50 million in revenue by the end of the year[12]. - The company is expanding its market presence, targeting new regions in Southeast Asia, with plans to establish two new distribution centers by Q4 2023[12]. - A strategic acquisition of a local competitor is in progress, which is anticipated to enhance market share by 10% and increase production capacity[12]. - The company is developing a 10GW N-type high-efficiency monocrystalline silicon wafer project, which is expected to enhance solar cell conversion efficiency[3]. - The company is focusing on the development of advanced photovoltaic packaging materials and products, with an 8GW project currently under construction[3]. Research and Development - The company has invested RMB 30 million in R&D for new technologies aimed at improving product efficiency and sustainability[12]. - Research and development expenses increased by 6.84% to 18.1 million RMB, reflecting the company's commitment to enhancing its product offerings[39]. - The company has a significant focus on research and development in new products and technologies within the chemical sector[112]. Environmental Compliance and Sustainability - The company has emphasized the importance of environmental protection and has been investing in improving its environmental management systems[54]. - The company was listed as a key pollutant discharge unit by the local environmental authority, indicating a focus on environmental protection and compliance[54]. - The company has implemented a comprehensive wastewater treatment system that includes three sets of distillation systems for ammonia recovery, ensuring compliance with discharge standards[3]. - The company has achieved ultra-low emissions for boiler flue gas through advanced treatment technologies, ensuring that emissions meet regulatory standards[3]. - The company actively responds to carbon peak and carbon neutrality goals, implementing measures to reduce greenhouse gas emissions and enhance resource recycling[64]. Financial Position and Assets - The company has maintained a strong cash position, with cash reserves amounting to RMB 200 million, ensuring liquidity for future investments[12]. - The company has a total asset value of approximately CNY 24.10 billion, a decrease of 1.61% from the end of the previous year[17]. - The company reported a significant decrease in contract liabilities by 68.16% to ¥74,447,563.73, representing 0.31% of total liabilities, mainly due to a reduction in advance payments received[40]. - The company has a total of ¥114,427,998.37 in restricted cash, which includes deposits for letters of credit and guarantees[195]. Shareholder and Corporate Governance - The largest shareholder, Sichuan Hebang Investment Group Co., Ltd., held 1,963,779,103 shares, accounting for 22.24% of the total shares[79]. - The company held its first extraordinary general meeting of shareholders on March 17, 2023, where it approved the proposal for issuing convertible bonds to unspecified objects[48]. - The second extraordinary general meeting took place on April 7, 2023, where the proposal for the dismissal of a director was approved[49]. - The company conducted a board and senior management reshuffle during the reporting period, with several new directors and supervisors elected[50]. Risks and Challenges - No significant risks were identified that could materially impact the company's operations during the reporting period[12]. - The company faces risks related to market price fluctuations affecting performance and uncertainties regarding the expected benefits of ongoing projects[47]. Taxation and Compliance - The company is expected to pay corporate income tax at a rate of 15% for the year 2023, in line with the preferential tax policies for enterprises in the western region[192]. - The company continues to benefit from tax incentives aimed at supporting small and micro enterprises, which will remain in effect until December 31, 2027[192].

四川和邦生物科技股份有限公司 2023 年半年度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据上海证券交易所《上市公司自律监管指引第 3 号行业信息披露：第十三号 ——化工》及相关要求，四川和邦生物科技股份有限公司（以下简称"公司"）现 将 2023 年 1-6 月主要经营数据披露如下： 一、主要产品的产量、销量及收入实现情况 | 主要产品 | 产量（吨） | 销量（吨） | 营业收入（万元） | | --- | --- | --- | --- | | 联碱化工类产品 | 1,275,036.35 | 908,965.50 | 171,155.86 | | 农药及中间体、副产品 | 103,585.89 | 50,526.42 | 61,938.81 | | 营养剂及中间体、副产品 | 66,186.31 | 42,622.50 | 15,887.51 | 注 1：联碱化工类产品包括：碳酸钠、氯化铵； 注 2：农药及中间体、副产品包括：双甘膦、草甘膦原粉、硫酸铵、磷酸氢二钠等； 证券代码：603077 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本投资意向书约定的投资项目尚处于初期阶段，具体实施时间、步骤及范 围存在变动可能性。 ●特别风险提示： 证券代码：603077 证券简称：和邦生物 公告编号：2023-49 四川和邦生物科技股份有限公司 关于签署《合作投资意向书》等的公告 同时，公司与印度尼西亚PT AKR Corporindo Tbk（以下简称"AKR"）（AKR 下属公司持有BKMS60%的股份）签署了《合作投资意向书》，约定在JIIPE成立一 家合资公司，其中公司（或公司的任何关联公司或子公司）持有90%股份，AKR（或 其任何关联公司或子公司）持有10%股份，作为印尼项目的投资、建设、运营实 体。 公司于2023年8月28日召开第六届董事会第二次会议，以9票同意、0票反对、 0票弃权的表决结果审议通过了《关于签署合作投资意向书的议案》。 本项目投资及相关合同的签署不构成《上市公司重大资产重组管理办法》规 定的重大资产重组，亦不构成关联交易。 3、投资意向书约定的投资项目投资金额较大，虽然 ...

关于四川和邦生物科技股份有限公司 向不特定对象发行可转换公司债券申请 上市审核委员会会议意见落实函的回复 保荐人（主承销商） （成都市高新区天府二街 198 号） 二〇二三年八月 上海证券交易所： 一、请发行人在募集说明书重大事项提示中结合双甘膦下游产品草甘膦市场 需求、技术路线及发展趋势，充分揭示募投项目产能消化的风险，并突出相关表 述 贵所于 2023 年 6 月 21 日出具的《关于四川和邦生物科技股份有限公司向不特 定对象发行可转债的上市审核委员会会议意见落实函》（以下简称"落实函"）已 收悉，四川和邦生物科技股份有限公司（以下简称"和邦生物""发行人"或"公 司"）会同华西证券股份有限公司（以下简称"保荐机构"）对落实函问题认真进 行了逐项落实，现回复如下，请予审核。 如无特别说明，本回复中的简称与《四川和邦生物科技股份有限公司向不特定 对象发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）中的简称 具有相同含义；本回复若出现各分项数值之和与总数尾数不符的情况，均为四舍五 入原因造成；涉及对发行人申请文件修改的内容已用楷体加粗标明。 | 落实函所列问题 | 黑体、加粗 | | --- | ...

四川和邦生物科技股份有限公司 Sichuan Hebang Biotechnology Co., Ltd. 注册地址：乐山市五通桥区牛华镇沔坝村 股票简称：和邦生物 股票代码：603077 向不特定对象发行可转换公司债券 二〇二三年八月 募集说明书 （上会稿） （修订稿） 保荐机构（主承销商） 四川和邦生物科技股份有限公司 可转换公司债券募集说明书 声 明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行 人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与 之相反的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由 发行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自 行承担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资 风险。 1-1-1 四川和邦生物科技股份有限公司 可转换公司债券募集说明书 重大事项提示 公司特别提示投资者对下列重大事项给予充分关注，并仔细阅读本募集说 明书中有关风险因素的章节。 一、公司本次募集资金投资项目基本情况 ...

证券代码：603077 证券简称：和邦生物 公告编号：2023-47 四川和邦生物科技股份有限公司 关于向不特定对象发行可转换公司债券 上市审核委员会会议意见落实函的回复公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 四川和邦生物科技股份有限公司（以下简称"公司"）于 2023 年 6 月 21 日收 到上海证券交易所(以下简称"上交所")出具的《关于四川和邦生物科技股份有限 公司向不特定对象发行可转债的上市审核委员会会议意见落实函》(上证上审(再融 资)[2023]421 号)(以下简称"《落实函》")。 公司收到《落实函》后，按照要求会同相关中介机构对相关问题进行了逐项落 实，并按要求提交了相关文件，具体内容详见公司同日披露于上海证券交易所网站 （www.sse.com.cn）的《关于四川和邦生物科技股份有限公司向不特定对象发行可 转换公司债券申请上市审核委员会会议意见落实函的回复》等文件。 公司本次向不特定对象发行可转换公司债券事项尚需获得中国证券监督管理委 员会（以下简称"中国证监会"）作出同意注册的决定后方可实 ...

四川和邦生物科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩 暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 证证券代码：603077 证券简称：和邦生物 公告编号：2023-40 http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 06 月 02 日(星期五) 至 06 月 08 日(星期四) 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 yd@hebang.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行 回答。 四川和邦生物科技股份有限公司（以下简称"公司"）已于 2023 年 2 月 21 日发布公司 2022 年度报告，于 2023 年 4 月 29 日发布公司 2023 年第一季度报 告，为便于广大投资者更全面深入地了解公司 2022 年度、2023 年第一季度经 营成果、财务状况，公司计划于 2023 年 06 月 09 日下午 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥2,394,468,174.84, a decrease of 22.41% compared to the same period last year[4] - Net profit attributable to shareholders was ¥396,561,190.75, down 61.97% year-on-year[4] - The net cash flow from operating activities was ¥347,430,102.23, reflecting a decline of 42.92% compared to the previous year[4] - Basic and diluted earnings per share were both ¥0.0455, representing a decrease of 62.08% year-on-year[4] - The weighted average return on equity was 2.05%, a decrease of 4.83 percentage points from the previous year[4] - The company experienced a significant decline in sales volume and gross profit, impacting overall financial performance[7] - The net profit for Q1 2023 was CNY 381,460,623.90, a decrease of 63.5% compared to CNY 1,045,126,299.13 in Q1 2022[18] - Operating profit for Q1 2023 was CNY 477,206,214.04, down 61.2% from CNY 1,230,073,011.36 in the same period last year[18] - Total revenue from operating activities was CNY 1,914,538,269.42, a decline from CNY 2,202,926,260.42 in Q1 2022[22] - The company reported a decrease in total comprehensive income to CNY 370,228,317.28, compared to CNY 1,045,773,792.08 in the previous year[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥24,037,510,067.91, a slight decrease of 0.27% from the end of the previous year[5] - The total assets as of March 31, 2023, were CNY 24,037,510,067.91, a slight decrease from CNY 24,102,627,180.48 at the end of 2022[16] - The total liabilities decreased to CNY 3,867,668,111.54 from CNY 4,339,408,910.04, indicating a reduction of about 10.8%[15] - The total liabilities amounted to 4,340,960,469.09 RMB, with a slight increase of 1,551,559.05 RMB from the previous reporting period[26] - The total current assets were reported at 9,718,871,752.72 RMB, consistent with the previous period[25] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 2.21% to ¥19,541,572,552.22 compared to the end of the previous year[5] - The company's equity attributable to shareholders increased to CNY 19,541,572,552.22 from CNY 19,118,356,709.62, reflecting a growth of approximately 2.2%[16] - The total equity attributable to shareholders was 19,118,356,709.62 RMB, remaining stable compared to the previous period[26] Cash Flow and Expenses - Cash flow from operating activities netted CNY 347,430,102.23, down 42.9% from CNY 608,684,674.99 in Q1 2022[22] - The total amount of cash received from sales and services was CNY 1,831,836,825.36, down from CNY 2,150,617,492.61 in Q1 2022[20] - The company incurred financial expenses of CNY 4,888,913.82, a decrease from CNY 7,822,077.06 in the same quarter last year[18] - The company reported a significant reduction in tax expenses to CNY 95,123,195.45 from CNY 182,502,911.84 in the previous year[18] - The net cash flow from financing activities for Q1 2023 was -192,397,264.30 RMB, a significant decrease compared to 705,492,807.09 RMB in Q1 2022[23] - The total cash and cash equivalents at the end of Q1 2023 amounted to 4,521,617,841.20 RMB, down from 2,743,067,767.20 RMB at the end of Q1 2022[23] - The net increase in cash and cash equivalents for Q1 2023 was -23,240,242.97 RMB, contrasting with an increase of 1,062,070,010.26 RMB in Q1 2022[23] Inventory and Receivables - Accounts receivable increased to CNY 967,737,627.47 in Q1 2023 from CNY 777,990,967.77 in Q1 2022, reflecting a growth of about 24.4%[14] - Inventory as of March 31, 2023, was CNY 2,340,898,666.66, compared to CNY 2,076,049,121.12 in the previous year, marking an increase of approximately 12.7%[14] - The company's inventory stood at 2,076,049,121.12 RMB, unchanged from the previous reporting period[25] - The total amount of accounts receivable was reported at 777,990,967.77 RMB, remaining stable compared to the previous period[24] Research and Development - Research and development expenses increased to CNY 9,108,322.93, up 18.7% from CNY 7,666,274.21 in Q1 2022[18] Production Developments - The company is progressing with the development of a 1,000t/d photovoltaic glass panel production line, which has officially commenced production[11]